Compare CDW Corp. (CDW) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CDW Corp. vs Stryker Corporation — how do they compare? CDW Corp. trades at $133.88 (market cap $17.81B), while Stryker Corporation trades at $316.62 (market cap $119.25B). The key difference: Stryker Corporation is far larger — about 6.7× CDW Corp.'s market cap, and CDW Corp. pays the higher dividend (1.81%). Which is the better fit depends on your goals.
| CDW | SYK | |
|---|---|---|
Market Cap | $17.81B | $119.25B |
Sector | Technology | Technology |
52-Week High | $182.18 | $403.53 |
52-Week Low | $99.30 | $282.58 |
Enterprise Value | $23.02B | $131.01B |
Dividend Yield | 1.81% | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CDW trades at $144.36, down slightly by 0.02% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $145.83. The company reported Q1 2026 earnings that met expectations with $2.28 EPS, following beats in previous quarters. Revenue for 2025 was $22.42B with a net income margin of 4.7%, while valuation metrics show a P/E of 17.58 and P/S of 0.83. Recent news highlights AI infrastructure demand and a $1B share repurchase authorization.
The outlook for CDW is positive, driven by AI growth opportunities and strong profitability, but risks include margin pressure and competitive threats. Analysts are bullish with 70.59% buy ratings, suggesting potential upside from current levels, though investors should monitor execution on earnings targets and macroeconomic conditions.
Stryker (SYK) trades at $331.45, up 0.51% today, with strong analyst support (74% buy ratings) and a consensus price target of $388.44. The stock shows bullish technical signals despite a recent Q1 2026 earnings miss attributed to a temporary cyber disruption. Fundamentals remain solid with 2025 revenue of $25.12B, net income margin of 13.21%, and robust cash flow generation of $5.04B from operations.
Outlook remains positive with maintained full-year guidance and healthy end-market demand. Investment opportunity lies in the valuation discount to historical averages and innovation-driven growth. Key risks include cybersecurity vulnerabilities and competitive pressures in the medtech sector. The stock offers potential upside of 17% to consensus target with dividend stability as a Dividend Aristocrat.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CDW Corp.
CDW Corp is a value-added reseller operating in the U.S. (95% of sales) and Canada (5%). The company has more than 100,000 products on its line of cards that range from notebooks to data center software. Roughly half of CDW's revenue comes from midsize and large businesses, with the remaining from small businesses, government agencies, education institutions, and health-care organizations.
Read more on CDW →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
